At the same time when numerous clinical trials were already conducted to test the efficacy of DCs as cellular cancer vaccines it was revealed in human tumor biopsies as well as murine and rat tumor models that DCs in many malignancies present an impaired function, manifested in poor antigen processing and presentation, impaired migration and low presence of costimulatory molecules (Gabrilovich, 2004; Yang and Carbone, 2004). Here, CD276 is linked to neoplasm.